Pharmacological management of cystic fibrosis related diabetes

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Introduction: There are limited data from randomized clinical trials to guide optimal options for pharmacological treatment of cystic fibrosis related diabetes (CFRD). Current guidelines recommend insulin as the only treatment option for CFRD. Areas covered: Current guidelines for screening, diagnosis and pharmacological agents for treatment of impaired glucose tolerance and CFRD in patients with cystic fibrosis are reviewed. Insights from clinical studies examining the role of insulin therapy in CFRD are presented. Expert commentary: CFRD is the most common extra pulmonary complication of cystic fibrosis, and is primarily related to insulin insufficiency. Insulin is the treatment of choice for CFRD. Insulin treatment is associated with improvement in glycemic control, nutritional status and lung function. Current data does not support use of oral hypoglycemic agents for treatment of CFRD.

Original languageEnglish (US)
Pages (from-to)185-191
Number of pages7
JournalExpert Review of Clinical Pharmacology
Issue number2
StatePublished - Feb 1 2018

Bibliographical note

Publisher Copyright:
© 2018 Informa UK Limited, trading as Taylor & Francis Group.


  • CFRD
  • Cystic fibrosis
  • cystic fibrosis related diabetes
  • glucose intolerance


Dive into the research topics of 'Pharmacological management of cystic fibrosis related diabetes'. Together they form a unique fingerprint.

Cite this